Clover Biopharmaceuticals, a biotechnology company focused on developing novel and transformative biologic therapies, has raised about $9.5 million (RMB 62.8 million) in its Series A round led by Tianhe Life Sciences Venture Fund.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
